Predictive Oncology Inc. (NASDAQ: POAI) Confirms A
Post# of 281
(Total Views: 212)
Posted On: 09/16/2020 2:25:15 PM
Predictive Oncology Inc. (NASDAQ: POAI) Confirms Attendance at Upcoming LD 500 Microcap Investor Conference
- Predictive Oncology presenting at upcoming LD 500 investor conference
- Investor event will take place Sept. 1-4, 2020 and will feature 500 handpicked companies from across North American listed micro-cap universe
- Predictive Oncology specializes in applying data and artificial intelligence to cancer personalized medicine, drug discovery
Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has announced that it will be presenting at the upcoming LD 500, an investor conference set to take place in an entirely virtual setting Sept. 1-4, 2020 (http://nnw.fm/n5Dkx). With 500 handpicked companies in attendance, this year’s conference is set to be among the largest micro-cap focused events globally with thousands of investors expected to attend.
LD Micro, the organizer of the LD 500 conference, was founded in 2006 with the purpose of providing an independent news resource for investors focusing on the microcap space. Initially a newsletter highlighting unique companies, the event has transformed itself into a series of influential conferences held annually– bringing together some of today’s most interesting smaller and micro-cap publicly listed companies and investors focusing on the space.
The LD 500 conference will be the company’s most ambitious event to date, hosting a selection of 500 of North America’s most promising micro-cap companies over a series of four days. The virtual event is set to include a series of keynote addresses and one-on-one meetings, where investors will be able to meet with corporate management teams to receive updates on ongoing corporate operations while posing queries of their own.
“We are delighted to be hosting our virtual event in order to showcase some of the truly unique names in micro-cap,” stated LD Micro president Chris Lahiji. “There are many people and companies who are unable to attend our live events, due to any number of reasons, so we are happy to offer an additional way for companies to present to investors without taking a lot of time out of their day-to-day operations. While virtual events will never replace the experience of sitting in the same room as other humans, it is a great format for updating the investor community and getting increased exposure.”
Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. Through its subsidiary Helomics, POAI is bringing this cutting-edge technology to cancer research, where it’s working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors response to drugs. These models can be used both for clinical decision support and research into new therapies.
Meanwhile, the company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample to enable the development of a patient-specific treatment plan (http://nnw.fm/kGMxW).
For more information about the company, visit www.Predictive-Oncology.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Predictive Oncology presenting at upcoming LD 500 investor conference
- Investor event will take place Sept. 1-4, 2020 and will feature 500 handpicked companies from across North American listed micro-cap universe
- Predictive Oncology specializes in applying data and artificial intelligence to cancer personalized medicine, drug discovery
Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has announced that it will be presenting at the upcoming LD 500, an investor conference set to take place in an entirely virtual setting Sept. 1-4, 2020 (http://nnw.fm/n5Dkx). With 500 handpicked companies in attendance, this year’s conference is set to be among the largest micro-cap focused events globally with thousands of investors expected to attend.
LD Micro, the organizer of the LD 500 conference, was founded in 2006 with the purpose of providing an independent news resource for investors focusing on the microcap space. Initially a newsletter highlighting unique companies, the event has transformed itself into a series of influential conferences held annually– bringing together some of today’s most interesting smaller and micro-cap publicly listed companies and investors focusing on the space.
The LD 500 conference will be the company’s most ambitious event to date, hosting a selection of 500 of North America’s most promising micro-cap companies over a series of four days. The virtual event is set to include a series of keynote addresses and one-on-one meetings, where investors will be able to meet with corporate management teams to receive updates on ongoing corporate operations while posing queries of their own.
“We are delighted to be hosting our virtual event in order to showcase some of the truly unique names in micro-cap,” stated LD Micro president Chris Lahiji. “There are many people and companies who are unable to attend our live events, due to any number of reasons, so we are happy to offer an additional way for companies to present to investors without taking a lot of time out of their day-to-day operations. While virtual events will never replace the experience of sitting in the same room as other humans, it is a great format for updating the investor community and getting increased exposure.”
Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. Through its subsidiary Helomics, POAI is bringing this cutting-edge technology to cancer research, where it’s working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors response to drugs. These models can be used both for clinical decision support and research into new therapies.
Meanwhile, the company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample to enable the development of a patient-specific treatment plan (http://nnw.fm/kGMxW).
For more information about the company, visit www.Predictive-Oncology.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼